Literature DB >> 24774440

Stent placement for complex middle cerebral artery aneurysms.

Yu Zhou1, Peng-Fei Yang1, Qiang Li1, Rui Zhao1, Yi-Bin Fang1, Yi Xu1, Bo Hong1, Wen-Yuan Zhao1, Qing-Hai Huang1, Jian-Min Liu2.   

Abstract

BACKGROUND: To evaluate the safety and effectiveness of stent placement for ruptured or unruptured middle cerebral artery (MCA) aneurysms in a larger number.
METHODS: Between October 2003 and December 2012, data for 70 patients with 72 complex MCA aneurysms treated with stents at our institution were retrospectively collected and analyzed.
RESULTS: Eighty-five stents were successfully deployed in this series. However, failure of followed coiling was encountered in 2 (2.8%) tiny aneurysms of them. Of the 63 aneurysms treated with stent-assisted coiling, complete occlusion was achieved in 22 (34.9%), neck remnant in 15 (23.8%), and residual sac in 26 (36.5%). Of the 9 aneurysms treated with stent alone, the results were contrast stasis in 3 aneurysms and no change in 6. Procedure-related complications occurred in 9 (12.5%) procedures, including 7 of 27 (25.9%) with ruptured aneurysms and 2 of 45 (4.4%) with unruptured aneurysms, which resulted in 1 death and 5 disabilities. Univariate and multivariate analyses show that ruptured aneurysm is an independent factor for the outcome of these patients (odds ratio, 7.35; 95% confidence interval, 1.35-40.0). Angiographic follow-up results (mean, 10.5±8.8 months) showed that 72.1% (44 of 61) were completely occluded, 4.9% (3 of 61) recurred, and others were stable or had improved. Intrastent stenosis was observed in 1 (1.6%) patient, which was managed conservatively. During a clinical follow-up period ranging from 7 to 113 months (mean, 33.0±22.4 months), 1 disabled patient died from severe pneumonia, whereas the clinical status of the others had improved or was stable. Procedure-related morbidity/mortality during the follow-up for the ruptured and unruptured groups were 3.7%/3.7% and 0/0, respectively.
CONCLUSIONS: Our study shows that stent placement for the treatment of certain wide-neck MCA aneurysms is feasible, safe, and effective. However, stent placement for acutely ruptured MCA aneurysms harbors a much higher complication rate.
Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Stent; aneurysms; middle cerebral artery; ruptured; unruptured

Mesh:

Substances:

Year:  2014        PMID: 24774440     DOI: 10.1016/j.jstrokecerebrovasdis.2013.12.054

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  4 in total

1.  Stent-assisted coiling of intracranial aneurysms located on small vessels: midterm results with the LVIS Junior stent in 40 patients with 43 aneurysms.

Authors:  Faisal Alghamdi; Benjamin Mine; Ricardo Morais; Pietro Scillia; Boris Lubicz
Journal:  Neuroradiology       Date:  2016-03-05       Impact factor: 2.804

2.  The use of single low-profile visualized intraluminal support stent-assisted coiling in the treatment of middle cerebral artery bifurcation unruptured wide-necked aneurysm.

Authors:  Yazhou Yan; Zhangwei Zeng; Yina Wu; Jiachao Xiong; Kaijun Zhao; Bo Hong; Yi Xu; Jianmin Liu; Qinghai Huang
Journal:  Interv Neuroradiol       Date:  2020-01-24       Impact factor: 1.610

3.  Endovascular Treatment of Ruptured Middle Cerebral Artery Aneurysms With a Low-Profile Visualized Intraluminal Support Device.

Authors:  Gaici Xue; Yu Zhou; Peng Liu; Qiao Zuo; Pengfei Yang; Yibin Fang; Qiang Li; Rui Zhao; Yi Xu; Bo Hong; Qinghai Huang; Jianmin Liu
Journal:  Front Neurol       Date:  2021-01-28       Impact factor: 4.003

4.  Safety and Long-Term Efficacy Outcomes for Endovascular Treatment of Wide-Neck Bifurcation Aneurysms of the Middle Cerebral Artery: Insights From the SMART Registry.

Authors:  Reade De Leacy; Devin V Bageac; Neha Siddiqui; Richard J Bellon; Min S Park; Clemens M Schirmer; Keith B Woodward; Osama O Zaidat; Alejandro M Spiotta
Journal:  Front Neurol       Date:  2022-02-07       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.